# ANSWERS TO ESTIMATES QUESTIONS ON NOTICE 

## HEALTH AND AGEING PORTFOLIO

Supplementary Budget Estimates 2011-2012, 19 October 2011
Question: E11-189
OUTCOME 2: Access to Pharmaceutical Services
Topic: PHARMACEUTICAL BENEFITS SCHEME SAVINGS
Written Question on Notice
Senator Adams asked:
The MOU between the Department of Health and Ageing and Medicines Australia is expected to generate savings of $\$ 1.9$ billion over five years.

Please provide the Committee with an update of the savings generated to date, including:
a) The savings generated from the 2 per cent reduction applied on 1 February 2011 under clause 11.
b) The savings generated from the 5 per cent reduction applied on 1 February 2011 under clause 12.
c) Details of any products that were exempt from the reductions, including an explanation of why they were exempt.
d) Please provide the Committee with the details of any products that have received a price cut of 16 per cent under clause 20.
e) Please provide the price before the 16 per cent cut was applied.

Answer:
a) and b)

As announced on 16 December 2011, the new prices for drugs subject to the Expanded and Accelerated Price Disclosure (EAPD) program which will come into effect on 1 April 2012, will ensure the Government achieves the $\$ 1.9$ billion in savings anticipated under the Memorandum of Understanding signed with Medicines Australia. This $\$ 1.9$ billion saving includes the EAPD savings, the savings from the one-off 2 per cent and 5 per cent statutory price reductions on 1 February 2011, and the increase from 12.5 per cent to 16 per cent of the statutory price reduction applied to a drug when it first becomes subject to brand competition.

The 2 per cent and 5 per cent statutory price reductions applied to all Pharmaceutical Benefits Scheme (PBS) listed brands of non-exempt pharmaceutical items containing drugs which were listed on the F2A and F2T formularies as at 11 October 2010, respectively. These reductions were required under the National Health Act 1953 (the Act). The Act provided for exemptions from these price reductions in the following circumstances:

- Section 99ACG of the Act exempted pharmaceutical items from these reductions if a 12.5 per cent statutory price reduction or a price disclosure reduction had been applied previously; and
- Section 84AH of the Act empowers the Minister to determine, by legislative instrument, that a pharmaceutical item is an 'exempt item' if the pharmaceutical item satisfies the criteria in that section. The intention of this exemption is to encourage availability of presentations of drugs that are used by a demographic subgroup, for example, a liquid presentation for children.
c) Information on the items which were exempted from these statutory price reductions can be accessed through the PBS website www.pbs.gov.au and the Australian Government ComLaw website www.comlaw.gov.au and is reproduced in the following tables.

Table 1 - Items exempt from 1 February 2011 statutory price reductions because of previous 12.5 percent reduction (http://www.pbs.gov.au/info/industry/pricing)

| No. | Drug |  | Date of effect <br> (12.5\% reduction) |
| :--- | :--- | :--- | :--- |
| 1 | Cefepime | Manner of Administration | 1-Dec-10 |
| 2 | Cephazolin | Injection | 1-Dec-10 |
| 3 | Hydroxocobalamin | Injection | 1-Dec-10 |
| 4 | Macrogol 3350 | Oral | 1-Dec-10 |
| 5 | Omeprazole and <br> clarithromycin and amoxicillin | Oral | 1-Dec-10 |
| 6 | Tacrolimus | Oral | 1-Dec-10 |

Table 2 - Items exempt from 1 February 2011 statutory price reductions because of a previous price disclosure price reduction (http://www.pbs.gov.au/infolindustry/pricing)

| No. | Drug | Manner of Administration | Date of effect <br> (Price disclosure <br> reduction) |
| :--- | :--- | :--- | :--- |
| 1 | Carvedilol | Oral | 1-Apr-10 |
| 2 | Fluconazole | Oral | 1-Apr-10 |
| 3 | Vancomycin | Injection | 1-Apr-10 |
| 4 | Cefalotin | Injection | 1-Aug-10 |
| 5 | Doxorubicin | Injection/intravesical | 1-Aug-10 |
| 6 | Meloxicam | Oral | 1-Aug-10 |
| 7 | Mitozantrone | Injection | 1-Aug-10 |
| 8 | Ondansetron | Injection | 1-Aug-10 |

Table 3 - Items exempt from statutory price reductions under section 84AH of the Act (see also PB58 of 2007 - Exempt Item Determination, http://www.comlaw.gov.au)

| No. | Drug | Form/Strength | Manner of administration |
| :---: | :---: | :---: | :---: |
| 1 | Amisulpride | Oral solution 100 mg per mL, 60 mL | Oral |
| 2 | Amoxycillin | Powder for paediatric oral drops 100 mg (as trihydrate) per mL, 20 mL | Oral |
| 3 | Artemether with Lumefantrine | Tablet (dispersible) $20 \mathrm{mg}-120 \mathrm{mg}$ | Oral |
| 4 | Baclofen | Intrathecal injection 10 mg in 5 mL | Injection |
| 5 | Captopril | Oral solution 5 mg per mL, 95 mL | Oral |
| 6 | Carbamazepine | Oral suspension 100 mg per $5 \mathrm{~mL}, 300 \mathrm{~mL}$ | Oral |
| 7 | Ciprofloxacin | Ear drops 3 mg (as hydrochloride) per mL, 5 mL | Application to the ear |
| 8 | Clonazepam | Oral liquid 2.5 mg per mL, 10 mL | Oral |
| 9 | Clonazepam | Injection 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent) | Injection |
| 10 | Clozapine | Oral liquid 50 mg per mL, 100 mL | Oral |
| 11 | Cyclosporin | Oral liquid 100 mg per mL, 50 mL | Oral |


| No. | Drug | Form/Strength | Manner of administration |
| :---: | :---: | :---: | :---: |
| 12 | Cyclosporin | Capsule 10 mg | Oral |
| 13 | Cyclosporin | Solution concentrate for I.V. infusion 50 mg in 1 mL | Injection |
| 14 | Diazepam | Injection 10 mg in 2mL | Injection |
| 15 | Diclofenac | Suppository containing diclofenac sodium 100 mg | Rectal |
| 16 | Digoxin | Paediatric oral solution 50 micrograms per mL, 60 mL | Oral |
| 17 | Erythromycin | Powder for I.V. infusion 1 g (as lactobionate) | Injection |
| 18 | Escitalopram | Oral solution 10 mg (as oxalate) per mL, 28 mL | Oral |
| 19 | Fluconazole | Powder for oral suspension 50 mg in 5 mL , 35 mL | Oral |
| 20 | Frusemide | Oral solution 10 mg per mL, 30 mL | Oral |
| 21 | Glyceryl trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | Sublingual |
| 22 | Indomethacin | Suppository 100 mg | Rectal |
| 23 | Ketoprofen | Suppository 100 mg | Rectal |
| 24 | Lacosamide | Oral solution 15 mg per mL, 200 mL | Oral |
| 25 | Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral |
| 26 | Levodopa with Carbidopa | Tablet $200 \mathrm{mg}-50 \mathrm{mg}$ (anhydrous) (modified release) | Oral |
| 27 | Methadone | Oral liquid containing methadone hydrochloride 25 mg per $5 \mathrm{~mL}, 200 \mathrm{~mL}$ | Oral |
| 28 | Methadone | Injection containing methadone hydrochloride 10 mg in 1 mL | Injection |
| 29 | Metronidazole | Suppositories 500 mg , 10 | Rectal |
| 30 | Metronidazole | Oral suspension containing metronidazole benzoate 320 mg per $5 \mathrm{~mL}, 100 \mathrm{~mL}$ | Oral |
| 31 | Naproxen | Oral suspension 125 mg per 5 mL , 474 mL | Oral |
| 32 | Nevirapine | Oral suspension 50 mg (as hemihydrate) per $5 \mathrm{~mL}, 240 \mathrm{~mL}$ | Oral |
| 33 | Oestradiol | Vaginal tablets 25 micrograms, 15 | Vaginal |
| 34 | Ondansetron | Syrup 4 mg (as hydrochloride dihydrate) per $5 \mathrm{~mL}, 50 \mathrm{~mL}$ | Oral |
| 35 | Paracetamol | Oral liquid 120 mg per $5 \mathrm{~mL}, 100 \mathrm{~mL}$ | Oral |
| 36 | Paracetamol | Oral liquid 240 mg per $5 \mathrm{~mL}, 200 \mathrm{~mL}$ | Oral |
| 37 | Paracetamol | Tablet 665 mg (modified release) | Oral |
| 38 | Paracetamol | Suppositories 500 mg , 24 | Rectal |
| 39 | Prochlorperazine | Suppositories containing prochlorperazine equivalent to 25 mg prochlorperazine maleate, 5 | Rectal |
| 40 | Prochlorperazine | Injection containing prochlorperazine mesylate 12.5 mg in 1 mL | Injection |
| 41 | Ranitidine | Syrup 150 mg (as hydrochloride) per 10 mL , 300 mL | Oral |
| 42 | Risperidone | Oral solution 1mg per mL, 100 mL | Oral |
| 43 | Roxithromycin | Tablet for oral suspension 50 mg | Oral |
| 44 | Salbutamol | Oral solution 2 mg (as sulfate) per $5 \mathrm{~mL}, 150 \mathrm{~mL}$ | Oral |
| 45 | Salbutamol | Pressurised inhalation in breath actuated device 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation) | Inhalation by mouth |
| 46 | Terbinafine | Cream containing terbinafine hydrochloride 10 mg per $\mathrm{g}, 15 \mathrm{~g}$ | Application |
| 47 | Tipranavir | Oral liquid 100 mg per mL, 95mL | Oral |
| 48 | Tramadol | Oral drops containing tramadol hydrochloride 100 mg per $\mathrm{mL}, 10 \mathrm{~mL}$ | Oral |
| 49 | Valganciclovir | Powder for oral solution 50 mg (as hydrochloride) per mL, 100mL | Oral |
| 50 | Valproic acid | Tablet, crushable, containing sodium valproate 100 mg | Oral |
| 51 | Valproic acid | Oral liquid containing sodium valproate 200 mg per $5 \mathrm{~mL}, 300 \mathrm{~mL}$ | Oral |
| 52 | Valproic acid | Oral solution containing sodium valproate 200 mg per $5 \mathrm{~mL}, 300 \mathrm{~mL}$ | Oral |


| No. | Drug | Form/Strength | Manner of <br> administration |
| :--- | :--- | :--- | :--- |
| 53 | Verapamil | Injection containing verapamil hydrochloride 5 mg <br> in 2 mL | Injection |

d) and e)

Tables 1, 2 and 3 below provide details of the pharmaceutical items which took a 16 per cent statutory price reduction on 1 April 2011, 1 August 2011 or 1 December 2011, the three occasions on which these reductions have taken place since the increase to 16 per cent was introduced. The tables also provide the price (dispensed price maximum quantity) before and after the price reduction.

Table 1 - Pharmaceutical Items which took a 16 percent statutory price reduction on 1 April 2011

| No. | Drug | Form/Strength | $\begin{aligned} & \text { Pack } \\ & \text { Size } \\ & \hline \end{aligned}$ | $\begin{aligned} & \text { Ma } \\ & \text { x } \\ & \text { Qty } \\ & \hline \end{aligned}$ | Feb 11 <br> Dispensed <br> Price <br> Maximum <br> Quantity ${ }^{\ddagger}$ | Apr 11 <br> Dispensed <br> Price <br> Maximum <br> Quantity ${ }^{\ddagger}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | Atenonol | Tablet 50mg | 30 | 30 | \$10.08 | \$9.49 |
| 2 | Epirubicin Hydrochloride | Solution for injection 100 mg in 50ml | 1 | 2 | \$906.84 | \$762.78 |
| 3 | Epirubicin Hydrochloride | Solution for injection 10 mg in 5 ml | 1 | 4 | \$208.26 | \$176.30 |
| 4 | Epirubicin Hydrochloride | Solution for injection 200 mg in 100ml | 1 | 1 | \$893.34 | \$751.43 |
| 5 | Epirubicin Hydrochloride | Solution for injection 20 mg in 10ml | 1 | 4 | \$379.30 | \$322.50 |
| 6 | Epirubicin Hydrochloride | Solution for injection 50 mg in $25 \mathrm{ml}$ | 1 | 4 | \$919.10 | \$773.06 |
| 7 | Filgrastim | Injection 300 mcg in 1 ml or in 0.5 ml single use pre-filled syringe | 10 | 20 | \$3,008.00* | \$2,515.54* |
| 8 | Filgrastim | Injection 480 mcg in 1.6 ml or in 0.5 ml single use pre-filled syringe | 10 | 20 | \$4,814.00* | \$4,032.58* |
| 9 | Idarubicin Hydrochloride | Solution for IV injection 10mg in 10 ml | 6 | 6 | \$2,104.80 | \$1,778.41 |
| 10 | Idarubicin Hydrochloride | Solution for IV injection 5mg in 5 ml | 3 | 3 | \$568.88 | \$478.89 |
| 11 | Isotretinoin | Capsule 10mg | 60 | 60 | \$89.37 | \$76.09 |
| 12 | Isotretinoin | Capsule 20 mg | 60 | 60 | \$135.70 | \$115.02 |
| 13 | Isotretinoin | Capsule 40mg | 30 | 30 | \$123.11 | \$104.44 |
| 14 | Pioglitazone | Tablet 15 mg (as hydrochloride) | 28 | 28 | \$61.52 | \$53.00 |
| 15 | Pioglitazone | Tablet 30 mg (as hydrochloride) | 28 | 28 | \$91.19 | \$77.62 |
| 16 | Pioglitazone | Tablet 45 mg (as hydrochloride) | 28 | 28 | \$116.64 | \$99.01 |
| 17 | Risedronate Sodium | Tablet 150mg | 1 | 1 | \$56.98 | \$49.53 |
| 18 | Risedronate Sodium | Tablet 30mg | 28 | 28 | \$304.62 | \$259.79 |
| 19 | Risedronate Sodium | Tablet 35mg | 4 | 4 | \$53.34 | \$46.55 |
| 20 | Risedronate Sodium | Tablet 5mg | 28 | 28 | \$53.34 | \$46.55 |
| 21 | Risedronate Sodium and | Pack containing 4 tablets risedronate sodium 30 mg and | 1 | 1 | \$53.34 | \$46.55 |


| No. | Drug | Form/Strength | Pack Size | Ma x Qty | Feb 11 <br> Dispensed Price Maximum Quantity ${ }^{\ddagger}$ | Apr 11 <br> Dispensed <br> Price <br> Maximum <br> Quantity ${ }^{\ddagger}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Calcium Carbonate | 24 tablets calcium carbonate 1.2 g (equivalent to 500 mg calcium) |  |  |  |  |
| 22 | Risedronate Sodium and Calcium Carbonate with Colecalciferol | Pack containing 4 tablets risedronate sodium 35 g and 24 sachets containing granules of calcium carbonate 2.5 g (equivalent to 1 g calcium) with colecalciferol 22 mcg | 1 | 1 | \$53.34 | \$46.55 |

$\ddagger$ General schedule prices, unless indicated otherwise. Dispensed price maximum quantity may not reflect exactly the $16 \%$ reduction as the reduction is calculated on the price exclusive of pharmacy mark ups and fees.
*Highly Specialised Drug (HSD) - public hospital price
Table 2 - Pharmaceutical Items which took a 16 percent statutory price reduction on
1 August 2011

| No. | Drug | Form/Strength | Pack Size | Max Qty | Apr 11 <br> Dispensed <br> Price <br> Maximum <br> Quantity ${ }^{\ddagger}$ | Aug 11 <br> Dispensed <br> Price <br> Maximum <br> Quantity ${ }^{\ddagger}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | Exemestane | Tablet 25 mg | 30 | 30 | \$180.18 | \$152.38 |
| 2 | Leflunomide | Tablet 10 mg | 30 | 30 | \$90.21 | \$76.80 |
| 3 | Leflunomide | Tablet 20 mg | 30 | 30 | \$133.99 | \$113.57 |
| 4 | Leflunomide | Pack containing 3 tablets leflunomide 100 mg and 30 tablets leflunomide 20 mg | 1 | 1 | \$207.57 | \$175.64 |
| 5 | Methylprednisolone | Powder for Injection 40 mg (as sodium succinate) | 5 | 5 | \$35.04 | \$30.47 |
| 6 | Methylprednisolone | Powder for Injection 1 g (as sodium succinate) | 1 | 1 | \$93.65 | \$79.69 |
| 7 | Methylprednisolone | Injection containing Methylprednisolone acetate 40 mg in 1 mL | 5 | 5 | \$24.23 | \$21.38 |
| 8 | Fentanyl | Transdermal patch 2.1 mg | 5 | 5 | \$47.16 | \$41.53 |
| 9 | Fentanyl | Transdermal patch 4.2 mg | 5 | 5 | \$56.28 | \$49.46 |
| 10 | Fentanyl | Transdermal patch 8.4 mg | 5 | 5 | \$95.38 | \$81.58 |
| 11 | Fentanyl | Transdermal patch 12.6 mg | 5 | 5 | \$127.28 | \$108.37 |
| 12 | Fentanyl | Transdermal patch 16.8 mg | 5 | 5 | \$155.76 | \$132.30 |
| 13 | Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation) | 1 | 2 | \$15.22 | \$13.82 |
| 14 | Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation) | 1 | 1 | \$10.82 | \$10.12 |


| No. | Drug | Form/Strength | Pack Size | Max Qty | Apr 11 <br> Dispensed <br> Price <br> Maximum <br> Quantity ${ }^{\ddagger}$ | Aug 11 <br> Dispensed <br> Price <br> Maximum <br> Quantity ${ }^{\ddagger}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 15 | Salbutamol | Capsule containing powder for oral inhalation 200 micrograms (as sulfate) (for use in Ventolin Rotahaler) | 100 | 200 | \$17.90 | \$16.06 |

$\ddagger$ General schedule prices, unless indicated otherwise. Dispensed price maximum quantity may not reflect exactly the $16 \%$ reduction as the reduction is calculated on the price exclusive of pharmacy mark ups and fees.

Table 3 - Pharmaceutical Items which took a 16 percent statutory price reduction on 1 December 2011

| No | Drug | Form/Strength | Pack <br> Size | $\begin{array}{\|l} \text { Max } \\ \text { Qty } \\ \hline \end{array}$ | Aug 11 <br> Dispensed <br> Price <br> Maximum <br> Quantity $\ddagger$ | Dec 11 <br> Dispensed <br> Price <br> Maximum <br> Quantity $\ddagger$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | Dexamethasone | Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL | 5 | 5 | \$18.08 | \$16.22 |
| 2 | Dexamethasone | Injection containing dexamethasone sodium phosphate equivalent to 8 mg dexamethasone phosphate in 2 mL | 5 | 5 | \$27.58 | \$24.20 |
| 3 | Temozolomide | Capsule 5 mg | 5 | 5 | \$73.75 | \$62.98 |
| 4 | Temozolomide | Capsule 20 mg | 5 | 5 | \$204.39 | \$172.71 |
| 5 | Temozolomide | Capsule 100 mg | 5 | 5 | \$808.22 | \$679.93 |
| 6 | Temozolomide | Capsule 140 mg | 5 | 5 | \$1,112.18 | \$935.25 |
| 7 | Temozolomide | Capsule 250 mg | 5 | 5 | \$1,863.31 | \$1,567.45 |

$\ddagger$ General schedule prices, unless indicated otherwise. Dispensed price maximum quantity may not reflect exactly the $16 \%$ reduction as the reduction is calculated on price exclusive of pharmacy mark ups and fees.

